China-headquartered contract research, development and manufacturing organization (CRDMO) WuXi Biologics plans to increase the manufacturing capacity of its US facility...
Chinese contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics announced the planned spin-off and separate listing of its subsidiary WuXi...
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...
29.05.2019
- Chinese contract development and manufacturing organization (CDMO) WuXi Biologics has signed a Letter of Intent (LoI) with a “global vaccine leader” to construct a dedicated...
